Monoclonal Antibodies against SARS-CoV-2 Full-Length S Protein
A panel of monoclonal antibodies against a purified, recombinant, full-length trimeric and stabilized version of recombinant S glycoprotein protein (190 kDa), expressed in Expi293F cells, is now available.1 These antibodies may play an important functional role on N-terminal domain (NTD) of S protein by binding to a distinct antigenic site on the NTD and disassociates S trimers by contacting critical residues in a cryptic hydrophobic pocket in the S protein. Of particular interest, neutralizing monoclonal antibody NR-56785 binds to a distinct antigenic site on S1.
Please choose the viral-specific anti-SARS-CoV-2 Spike antibody best suited for your research needs by viewing the technical details of each product.
Reference: 1. Mohammad, S., et al. “Development and Validation of a Rapid and Easy-to-Perform Point-of-Care Lateral Flow Immunoassay (LFIA) for the Detection of SARS-CoV-2 Spike Protein.” Front. Immunol. 14 (2023): 1111644. PubMed: 36911726.